Float Short %

2.66

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

2.09

EPS Last/This Y

1.06

EPS This/Next Y

8.81

Price

1.87

Target Price

Analyst Recom

Performance Q

-22.31

Relative Volume

0.81

Beta

1.94

Ticker: MBRX

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2024-12-19	MBRX	1.82	N/A	N/A	0
2024-12-20	MBRX	1.68	N/A	N/A	0
2024-12-23	MBRX	1.69	N/A	N/A	0
2024-12-24	MBRX	1.82	N/A	N/A	0
2024-12-26	MBRX	1.75	N/A	N/A	0
2024-12-27	MBRX	1.62	N/A	N/A	0
2024-12-30	MBRX	1.79	N/A	N/A	0
2024-12-31	MBRX	1.71	N/A	N/A	0
2025-01-02	MBRX	1.77	N/A	N/A	0
2025-01-03	MBRX	1.84	N/A	N/A	0
2025-01-06	MBRX	1.79	N/A	N/A	0
2025-01-07	MBRX	1.75	N/A	N/A	0
2025-01-08	MBRX	1.77	N/A	N/A	0
2025-01-09	MBRX	1.78	N/A	N/A	0
2025-01-10	MBRX	1.65	N/A	N/A	0
2025-01-13	MBRX	1.65	N/A	N/A	0
2025-01-14	MBRX	1.87	N/A	N/A	0
2025-01-15	MBRX	1.81	N/A	N/A	0
2025-01-16	MBRX	1.74	N/A	N/A	0
2025-01-17	MBRX	1.88	N/A	N/A	0
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2024-12-19	MBRX	1.81	-	-	-14.09
2024-12-20	MBRX	1.67	-	-	-14.09
2024-12-23	MBRX	1.73	-	-	-14.09
2024-12-24	MBRX	1.82	-	-	-14.09
2024-12-26	MBRX	1.77	-	-	-14.09
2024-12-27	MBRX	1.62	-	-	-14.09
2024-12-30	MBRX	1.81	-	-	-14.09
2024-12-31	MBRX	1.69	-	-	-14.09
2025-01-02	MBRX	1.79	-	-	-14.09
2025-01-03	MBRX	1.79	-	-	-14.09
2025-01-06	MBRX	1.79	-	-	-14.09
2025-01-07	MBRX	1.73	-	-	-14.09
2025-01-08	MBRX	1.78	-	-	-14.09
2025-01-09	MBRX	1.78	-	-	-14.09
2025-01-10	MBRX	1.64	-	-	-14.09
2025-01-13	MBRX	1.65	-	-	-14.09
2025-01-14	MBRX	1.87	-	-	-14.09
2025-01-15	MBRX	1.81	-	-	-14.09
2025-01-16	MBRX	1.78	-	-	-14.09
2025-01-17	MBRX	1.87	-	-	-14.09
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2024-12-19	MBRX	0.00	0	0.67
2024-12-20	MBRX	0.00	0	0.67
2024-12-23	MBRX	0.00	0	0.67
2024-12-24	MBRX	0.00	0	0.67
2024-12-26	MBRX	0.00	0	1.11
2024-12-27	MBRX	0.00	0	1.11
2024-12-30	MBRX	0.00	0	1.11
2024-12-31	MBRX	0.00	0	1.11
2025-01-02	MBRX	0.00	0	1.11
2025-01-03	MBRX	0.00	0	1.11
2025-01-06	MBRX	0.00	0	1.11
2025-01-07	MBRX	0.00	0	1.11
2025-01-08	MBRX	0.00	0	1.11
2025-01-09	MBRX	0.00	0	1.11
2025-01-10	MBRX	0.00	0	1.11
2025-01-13	MBRX	0.00	0.16	2.67
2025-01-14	MBRX	0.00	0.16	2.67
2025-01-15	MBRX	0.00	0.16	2.67
2025-01-16	MBRX	0.00	0.16	2.67
2025-01-17	MBRX	0.00	0.16	2.66
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-2.09

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

0.16

Beta

1.94

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-98.8

Target Price

P/E

Forward P/E

PEG

P/S

P/B

0.75

P/Free Cash Flow

EPS

-11.69

Average EPS Est. Cur. Y

-14.09

EPS Next Y. (Est.)

-5.28

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.81

Return on Equity vs Sector %

-422.2

Return on Equity vs Industry %

-409.6

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Moleculin Biotech, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 18

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

stock quote shares MBRX – Moleculin Biotech Inc Stock Price stock today

news today MBRX – Moleculin Biotech Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch MBRX – Moleculin Biotech Inc yahoo finance google finance

stock history MBRX – Moleculin Biotech Inc invest stock market

stock prices MBRX premarket after hours

ticker MBRX fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: MBRX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y